Browse

You are looking at 1 - 5 of 5 items for :

  • Asian - Indian x
  • Publication Details x
  • Case Report Type x
  • Country of Treatment x
Clear All
Mohammed Anwar Hussain Department of Endocrinology, Christian Medical College and Hospital, Vellore, India

Search for other papers by Mohammed Anwar Hussain in
Google Scholar
PubMed
Close
,
Aneez Joseph Department of Endocrinology, Christian Medical College and Hospital, Vellore, India

Search for other papers by Aneez Joseph in
Google Scholar
PubMed
Close
,
Vinoo Mathew Cherian Department of Orthopaedics, Christian Medical College and Hospital, Vellore, India

Search for other papers by Vinoo Mathew Cherian in
Google Scholar
PubMed
Close
,
Alok Srivastava Department of Haematology, Christian Medical College and Hospital, Vellore, India

Search for other papers by Alok Srivastava in
Google Scholar
PubMed
Close
,
Kripa Elizabeth Cherian Department of Endocrinology, Christian Medical College and Hospital, Vellore, India

Search for other papers by Kripa Elizabeth Cherian in
Google Scholar
PubMed
Close
,
Nitin Kapoor Department of Endocrinology, Christian Medical College and Hospital, Vellore, India

Search for other papers by Nitin Kapoor in
Google Scholar
PubMed
Close
, and
Thomas Vizhalil Paul Department of Endocrinology, Christian Medical College and Hospital, Vellore, India

Search for other papers by Thomas Vizhalil Paul in
Google Scholar
PubMed
Close

Summary

Although bisphosphonates (BPs) are mainly used for the treatment of osteoporosis and are generally safe, long-term use and more dosage as utilised in malignant conditions may be associated with the rare adverse event of an atypical femoral fracture (AFF). Occasionally, the risk of developing an AFF persists long after BPs are withdrawn. A 39-year-old woman who underwent chemotherapy and an autologous stem cell transplantation for multiple myeloma presented to us with history of pain in the left thigh. She had received multiple doses of oral and parenteral BPs for about 10 years in view of the underlying myeloma with osteoporosis. Her investigations showed a suppressed CTX of 192 pg/mL, and radiograph of pelvis displayed thickened cortices with beaking of the left femoral shaft, which was suggestive of an AFF. Following discontinuation of BPs, she underwent prophylactic intra-medullary nailing with which her symptoms improved. Five years later, she presented with similar complaints on the right side. Investigations showed that her bone turnover continued to be suppressed with Cross linked C- Telopeptide of type 1 collagen (CTX) of 165 pg/mL and an X-ray done showed AFF on the right side despite being off BPs. A second intra-medullary nailing was done and on follow-up, she has been symptom-free and independent in her daily activities. Discontinuation of BPs may not prevent the incident second AFF and, therefore, thus warranting long-term follow-up.

Learning points

  • Regular screening and follow-up of patients who receive long-term bisphosphonate (BP) therapy should be done.

  • Discontinuation of BPs does not preclude the possibility of repeated occurrence of a second AFF.

  • Long-term BP therapy warrants regular monitoring and follow-up should an AFF occur

Open access
Jenny S W Yun Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Search for other papers by Jenny S W Yun in
Google Scholar
PubMed
Close
,
Chris McCormack Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Search for other papers by Chris McCormack in
Google Scholar
PubMed
Close
,
Michelle Goh Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Search for other papers by Michelle Goh in
Google Scholar
PubMed
Close
, and
Cherie Chiang Department of Internal Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
University of Melbourne, Parkville, Victoria, Australia

Search for other papers by Cherie Chiang in
Google Scholar
PubMed
Close

Summary

Acanthosis nigricans (AN) is a common dermatosis associated with hyperinsulinemia and insulin resistance. However, AN has been rarely reported in patients with insulinoma, a state of persistent hyperinsulinemia. We present a case of metastatic insulinoma, in whom AN manifested after the first cycle of peptide receptor radionuclide therapy (PRRT). A 40-year-old man was diagnosed with metastatic insulinoma after 5 months of symptomatic hypoglycemia. Within 1 month post PRRT, the patient became euglycemic but developed a pigmented, pruritic rash which was confirmed on biopsy as AN. We discuss the rare manifestation of AN in subjects with insulinoma, the role of insulin in the pathogenesis of AN, malignant AN in non-insulin-secreting malignancies and association with other insulin-resistant endocrinopathies such as acromegaly.

Learning points

  • Acanthosis nigricans (AN) is a common dermatosis which is typically asymptomatic and associated with the hyperinsulinemic state.

  • Malignant AN can rapidly spread, cause pruritus and affect mucosa and the oral cavity.

  • AN is extremely rare in patients with insulinoma despite marked hyperinsulinemia.

  • Peptide receptor radionuclide therapy might have triggered TGF-α secretion in this subject which led to malignant AN.

  • Rapid spread or unusual distribution of pruritic AN warrants further investigation to exclude underlying malignancy.

Open access
David Kishlyansky Division of Internal Medicine, Department of Medicine, University of Calgary, Calgary, Alberta, Canada

Search for other papers by David Kishlyansky in
Google Scholar
PubMed
Close
,
Gregory Kline Divison of Endocrinology and Metabolism, Department of Medicine, University of Calgary, Calgary, Alberta, Canada

Search for other papers by Gregory Kline in
Google Scholar
PubMed
Close
,
Amita Mahajan Divison of Endocrinology and Metabolism, Department of Medicine, University of Calgary, Calgary, Alberta, Canada

Search for other papers by Amita Mahajan in
Google Scholar
PubMed
Close
,
Konstantin Koro Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada

Search for other papers by Konstantin Koro in
Google Scholar
PubMed
Close
,
Janice L Pasieka Divison of Endocrine surgery, Surgical Oncology and Endocrinology, Department of Surgery, University of Calgary, Calgary, Alberta, Canada

Search for other papers by Janice L Pasieka in
Google Scholar
PubMed
Close
, and
Patrick Champagne Department of Cardiac Sciences, University of Calgary, Calgary, Alberta, Canada

Search for other papers by Patrick Champagne in
Google Scholar
PubMed
Close

Summary

An adrenocorticotropic hormone (ACTH)-producing pheochromocytoma (PCC)/paraganglioma is the cause of ectopic Cushing’s syndrome (CS) in 5.2% of cases reported in the literature. We present a previously healthy 43-year-old woman admitted to our hospital with cushingoid features and hypertensive urgency (blood pressure = 200/120 mmHg). Her 24-h urinary free cortisol was >4270 nmol/day (reference range (RR) = 100–380 nmol/day) with a plasma ACTH of 91.5 pmol/L (RR: 2.0–11.5 pmol/L). Twenty-four-hour urinary metanephrines were increased by 30-fold. Whole-body CT demonstrated a 3.7-cm left adrenal mass with a normal-appearing right adrenal gland. Sellar MRI showed a 5-mm sellar lesion. MIBG scan revealed intense uptake only in the left adrenal mass. She was managed pre-operatively with ketoconazole and phenoxybenzamine and underwent an uneventful left laparoscopic adrenalectomy, which resulted in biochemical resolution of her hypercortisolemia and catecholamine excess. Histology demonstrated a PCC (Grading System for Adrenal Pheochromocytoma and Paraganglioma score 5) with positive ACTH staining by immunohistochemistry. A PCC gene panel showed no mutations and there has been no evidence of recurrence at 24 months. This case highlights the difficult nature of localizing the source of CS in the setting of a co-existing PCC and sellar mass.

Learning points

  • An adrenocorticotropic hormone (ACTH)-producing pheochromocytoma (PCC) is an important item to be considered in all patients presenting with ectopic Cushing’s syndrome (CS).

  • In exceptionally rare cases, patients with ectopic CS may present with multiple lesions, and a systematic approach considering all potential sources is crucial to avoid misdiagnosis.

  • CS with a large adrenal mass but lacking contralateral adrenal atrophy should raise suspicion of an ACTH-dependent process.

  • In patients with clinical suspicion of PCC, clinicians should be mindful of the use of steroids and beta-blockers without appropriate alpha blockade as they may precipitate an adrenergic crisis.

Open access
Ray Wang Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Parkville, Victoria, Australia

Search for other papers by Ray Wang in
Google Scholar
PubMed
Close
,
Benjamin Solomon Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia

Search for other papers by Benjamin Solomon in
Google Scholar
PubMed
Close
,
Stephen J Luen Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia

Search for other papers by Stephen J Luen in
Google Scholar
PubMed
Close
,
Owen W.J. Prall Department of Pathology, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia

Search for other papers by Owen W.J. Prall in
Google Scholar
PubMed
Close
,
Christine Khoo Department of Pathology, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia

Search for other papers by Christine Khoo in
Google Scholar
PubMed
Close
,
Anthony J Gill University of Sydney, Sydney, New South Wales, Australia

Search for other papers by Anthony J Gill in
Google Scholar
PubMed
Close
,
Jeremy Lewin Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia

Search for other papers by Jeremy Lewin in
Google Scholar
PubMed
Close
, and
Nirupa Sachithanandan Department of Internal Medicine, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia

Search for other papers by Nirupa Sachithanandan in
Google Scholar
PubMed
Close

Summary

Adrenocortical carcinoma is a rare disease with poor prognosis whose clinical heterogeneity can at times present a challenge to accurate and timely diagnosis. We present the case of a patient who presented with extensive pulmonary lesions, mediastinal and hilar lymphadenopathy and an adrenal mass in whom the oncological diagnosis was initially uncertain. Through the use of immunohistochemistry, biochemistry and genomic testing, an accurate diagnosis of adrenocortical carcinoma was ultimately made which resulted in more directed treatment being administered. The use of multidisciplinary input and genomics to aid in diagnosis and prognosis of adrenocortical carcinoma is discussed.

Learning points

  • Adrenocortical carcinomas can present a diagnostic challenge to clinicians given it is a rare malignancy with significant clinical heterogeneity.

  • Specialist multidisciplinary team input is vital in the diagnosis and management of adrenocortical carcinomas.

  • Hormonal testing is recommended in the diagnostic workup of adrenal masses, even in the absence of overt clinical signs/symptoms of hormone excess.

  • Immunostaining for the highly sensitive and specific steroidogenic factor-1 is vital for accurate diagnosis.

  • Genomics can provide prognostic utility in management of adrenocortical carcinoma.

Open access
Jayshree Swain Department of Endocrinology, Institute of Medical Sciences, Benaras Hindu University, Varanasi 221005, India

Search for other papers by Jayshree Swain in
Google Scholar
PubMed
Close
,
Shruti Sharma Department of Endocrinology, Institute of Medical Sciences, Benaras Hindu University, Varanasi 221005, India

Search for other papers by Shruti Sharma in
Google Scholar
PubMed
Close
,
Ved Prakash Department of Endocrinology, Institute of Medical Sciences, Benaras Hindu University, Varanasi 221005, India

Search for other papers by Ved Prakash in
Google Scholar
PubMed
Close
,
N K Agrawal Department of Endocrinology, Institute of Medical Sciences, Benaras Hindu University, Varanasi 221005, India

Search for other papers by N K Agrawal in
Google Scholar
PubMed
Close
, and
S K Singh Department of Endocrinology, Institute of Medical Sciences, Benaras Hindu University, Varanasi 221005, India

Search for other papers by S K Singh in
Google Scholar
PubMed
Close

Summary

Ovarian steroid cell tumors are very rare functioning sex-cord stromal tumors. They comprise <0.1% of all ovarian tumors. Previously designated as lipoid cell tumors, one-third of these tumors are considered malignant with the mean age of presentation at around 40 years. We present a case of a 28-year-old female with 2-year history of hirsutism, virilization, and amenorrhea. She was diagnosed with left ovarian tumor, for which she underwent left salpingo-oophorectomy. Histopathology revealed not otherwise specified subtype of steroid cell tumors. The patient resumed menses 2 months after the features of masculinization regressed. Within 1 year of surgery, the patient successfully conceived a full-term baby without any complications. In a young female, the neoplastic etiology of a rapid virilization or menses changing should always be kept in mind. Though commonly observed in adult females, steroid cell tumors have very good surgical outcomes if age at presentation is less and tumor is unilateral, and there are no evidences of bilateral malignancy. Bilateral salpingo-oophorectomy is not required.

Learning points

  • In a case of severe rapid hirsutism and virilization with serum testosterone level more than 200 ng/dl or more than threefold of the normal range, neoplastic conditions should always be suspected.

  • Steroid cell tumor in young women without evidence of malignancy on histopathology has excellent surgical outcomes.

  • Unilateral salpingo-oophorectomy is the surgery of choice.

  • As the frequency of bilateralism is only 6%, prophylactic unaffected side oophorectomy need not be done.

Open access